Outset Medical Reports Q4 Earnings Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy OM?
Source: seekingalpha
- Earnings Report Disappointment: Outset Medical reported a Q4 non-GAAP EPS of -$0.84, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Slight Revenue Decline: The company's Q4 revenue was $28.9 million, down 2.0% year-over-year, and while it met market expectations, the ongoing revenue decline may reflect weak market demand, necessitating a review of future sales strategies.
- Market Reaction Analysis: Given the earnings miss, Outset Medical's stock price may face downward pressure, prompting investors to carefully assess its future growth potential and competitive positioning in the market.
- Industry Outlook: In the context of increasing competition in the medical device sector, Outset Medical must implement effective measures to enhance product sales and market share to address future challenges and achieve sustainable growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OM
Wall Street analysts forecast OM stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.800
Low
7.00
Averages
11.75
High
17.00
Current: 3.800
Low
7.00
Averages
11.75
High
17.00
About OM
Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. Tablo Console is a proprietary, compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Outset Medical Reports Q4 2025 Earnings Highlights
- Financial Performance Boost: Outset Medical reported total revenue of $119.5 million for 2025, a 5% increase over 2024, with Q4 revenue at $28.9 million and product revenue at $19.9 million, indicating robust growth in the market.
- Margin Improvement: The non-GAAP gross margin reached 42.9% in Q4, expanding over 500 basis points year-over-year, with product gross margin exceeding 50% for the first time, showcasing significant progress in cost control and pricing strategies.
- High Customer Satisfaction: The Tablo system is now utilized at approximately 1,000 acute care sites in the U.S., with customer satisfaction remaining above 95%, reflecting the company's ongoing commitment to customer service and product quality.
- Optimistic Future Outlook: The company anticipates 2026 revenue between $125 million and $130 million, representing a growth rate of 5% to 9%, while gross margins are expected to remain in the low to mid-40% range, demonstrating confidence in future growth.
See More
Outset Medical Reports Q4 Earnings Miss
- Earnings Report Disappointment: Outset Medical reported a Q4 non-GAAP EPS of -$0.84, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Slight Revenue Decline: The company's Q4 revenue was $28.9 million, down 2.0% year-over-year, and while it met market expectations, the ongoing revenue decline may reflect weak market demand, necessitating a review of future sales strategies.
- Market Reaction Analysis: Given the earnings miss, Outset Medical's stock price may face downward pressure, prompting investors to carefully assess its future growth potential and competitive positioning in the market.
- Industry Outlook: In the context of increasing competition in the medical device sector, Outset Medical must implement effective measures to enhance product sales and market share to address future challenges and achieve sustainable growth.
See More
Outset Medical to Announce Q4 Earnings on February 11
- Earnings Announcement Schedule: Outset Medical (OM) is set to release its Q4 2023 earnings on February 11 after market close, with a consensus EPS estimate of -$0.68, reflecting an 83.8% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations Decline: Analysts project quarterly revenue of $28.9 million, down 2.0% year-over-year, suggesting that the company may face competitive pressures that could hinder its future growth potential.
- Historical Performance Review: Over the past two years, OM has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, indicating some capacity to exceed expectations, although recent downward revisions may impact investor confidence.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have had no upward revisions and one downward revision, reflecting a cautious market outlook on OM's future performance.
See More
Outset Medical Secures FDA 510(k) Clearance for Next-Gen Tablo Platform
- FDA Clearance Milestone: Outset Medical's next-generation Tablo platform has received FDA 510(k) clearance, becoming the first hemodialysis system to comply with the latest 2025 cybersecurity guidelines, underscoring the company's leadership in medical technology innovation.
- Cybersecurity Enhancements: The new platform incorporates enterprise-grade cybersecurity at the hardware, software, and cloud levels, designed to meet modern hospital IT standards, thereby enhancing security and reliability for dialysis providers in hospitals and homes.
- Performance Improvements: With modernization of the operating system, hardware upgrades, and software enhancements, the Tablo platform's system performance is significantly improved, expected to extend the time between planned maintenance in high-acuity environments, thus increasing healthcare service efficiency.
- Market Launch Plans: The new platform is expected to begin shipping to customers in Q2 2026, with existing Tablo users eligible for upgrades to this new cybersecurity platform, further enhancing their clinical and financial outcomes.
See More
Outset Medical Reports Q3 Earnings Miss, Stock Plummets 48.47%
- Earnings Miss: Outset Medical reported a non-GAAP loss of -$0.69 per share for Q3 2025, missing consensus estimates by $0.03, indicating significant pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company generated $29.43 million in revenue for the quarter, falling short of estimates by $1.27 million, reflecting weak sales growth that may complicate future financing efforts.
- Outlook Revision: Outset Medical revised its 2025 revenue guidance to a range of $115 million to $120 million, down from $122 million to $126 million, signaling delays in closing several large opportunities that could impact long-term strategic planning.
- Stock Plunge: Following the earnings report, Outset Medical's stock price fell by $5.85, or 48.47%, closing at $6.22, highlighting strong market concerns regarding the company's future performance.
See More
Osisko Metals Completes $32.48 Million Private Placement with Strategic Investors
- Successful Financing: Osisko Metals has completed a private placement with four strategic investors, issuing 67,666,666 common shares for approximately $32.48 million, reflecting strong market confidence in its future growth.
- Investor Participation: Hudbay Minerals subscribed for 29,166,666 shares for $14 million, while Agnico Eagle Mines invested $12.48 million for 26 million shares, indicating positive sentiment from major mining companies regarding Osisko's long-term potential.
- Equity Structure Changes: Hudbay and Agnico now hold approximately 4.3% and 9.85% of Osisko, respectively, with Hudbay granted rights for future participation, which could influence the company's governance structure.
- Project Advancement Funding: The net proceeds from this financing will be used to advance the Gaspé Copper project, including drilling and technical studies, which is expected to accelerate resource expansion and enhance the company's competitiveness in the copper market.
See More
Outset Medical Reports Q4 2025 Earnings Highlights
- Financial Performance Boost: Outset Medical reported total revenue of $119.5 million for 2025, a 5% increase over 2024, with Q4 revenue at $28.9 million and product revenue at $19.9 million, indicating robust growth in the market.
- Margin Improvement: The non-GAAP gross margin reached 42.9% in Q4, expanding over 500 basis points year-over-year, with product gross margin exceeding 50% for the first time, showcasing significant progress in cost control and pricing strategies.
- High Customer Satisfaction: The Tablo system is now utilized at approximately 1,000 acute care sites in the U.S., with customer satisfaction remaining above 95%, reflecting the company's ongoing commitment to customer service and product quality.
- Optimistic Future Outlook: The company anticipates 2026 revenue between $125 million and $130 million, representing a growth rate of 5% to 9%, while gross margins are expected to remain in the low to mid-40% range, demonstrating confidence in future growth.
See More
Outset Medical Reports Q4 Earnings Miss
- Earnings Report Disappointment: Outset Medical reported a Q4 non-GAAP EPS of -$0.84, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Slight Revenue Decline: The company's Q4 revenue was $28.9 million, down 2.0% year-over-year, and while it met market expectations, the ongoing revenue decline may reflect weak market demand, necessitating a review of future sales strategies.
- Market Reaction Analysis: Given the earnings miss, Outset Medical's stock price may face downward pressure, prompting investors to carefully assess its future growth potential and competitive positioning in the market.
- Industry Outlook: In the context of increasing competition in the medical device sector, Outset Medical must implement effective measures to enhance product sales and market share to address future challenges and achieve sustainable growth.
See More
Outset Medical to Announce Q4 Earnings on February 11
- Earnings Announcement Schedule: Outset Medical (OM) is set to release its Q4 2023 earnings on February 11 after market close, with a consensus EPS estimate of -$0.68, reflecting an 83.8% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Expectations Decline: Analysts project quarterly revenue of $28.9 million, down 2.0% year-over-year, suggesting that the company may face competitive pressures that could hinder its future growth potential.
- Historical Performance Review: Over the past two years, OM has beaten EPS estimates 50% of the time and revenue estimates 63% of the time, indicating some capacity to exceed expectations, although recent downward revisions may impact investor confidence.
- Estimates Revision Dynamics: In the last three months, EPS estimates have seen one upward revision and three downward revisions, while revenue estimates have had no upward revisions and one downward revision, reflecting a cautious market outlook on OM's future performance.
See More
Outset Medical Secures FDA 510(k) Clearance for Next-Gen Tablo Platform
- FDA Clearance Milestone: Outset Medical's next-generation Tablo platform has received FDA 510(k) clearance, becoming the first hemodialysis system to comply with the latest 2025 cybersecurity guidelines, underscoring the company's leadership in medical technology innovation.
- Cybersecurity Enhancements: The new platform incorporates enterprise-grade cybersecurity at the hardware, software, and cloud levels, designed to meet modern hospital IT standards, thereby enhancing security and reliability for dialysis providers in hospitals and homes.
- Performance Improvements: With modernization of the operating system, hardware upgrades, and software enhancements, the Tablo platform's system performance is significantly improved, expected to extend the time between planned maintenance in high-acuity environments, thus increasing healthcare service efficiency.
- Market Launch Plans: The new platform is expected to begin shipping to customers in Q2 2026, with existing Tablo users eligible for upgrades to this new cybersecurity platform, further enhancing their clinical and financial outcomes.
See More
Outset Medical Reports Q3 Earnings Miss, Stock Plummets 48.47%
- Earnings Miss: Outset Medical reported a non-GAAP loss of -$0.69 per share for Q3 2025, missing consensus estimates by $0.03, indicating significant pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company generated $29.43 million in revenue for the quarter, falling short of estimates by $1.27 million, reflecting weak sales growth that may complicate future financing efforts.
- Outlook Revision: Outset Medical revised its 2025 revenue guidance to a range of $115 million to $120 million, down from $122 million to $126 million, signaling delays in closing several large opportunities that could impact long-term strategic planning.
- Stock Plunge: Following the earnings report, Outset Medical's stock price fell by $5.85, or 48.47%, closing at $6.22, highlighting strong market concerns regarding the company's future performance.
See More
Osisko Metals Completes $32.48 Million Private Placement with Strategic Investors
- Successful Financing: Osisko Metals has completed a private placement with four strategic investors, issuing 67,666,666 common shares for approximately $32.48 million, reflecting strong market confidence in its future growth.
- Investor Participation: Hudbay Minerals subscribed for 29,166,666 shares for $14 million, while Agnico Eagle Mines invested $12.48 million for 26 million shares, indicating positive sentiment from major mining companies regarding Osisko's long-term potential.
- Equity Structure Changes: Hudbay and Agnico now hold approximately 4.3% and 9.85% of Osisko, respectively, with Hudbay granted rights for future participation, which could influence the company's governance structure.
- Project Advancement Funding: The net proceeds from this financing will be used to advance the Gaspé Copper project, including drilling and technical studies, which is expected to accelerate resource expansion and enhance the company's competitiveness in the copper market.
See More
